ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysis - Sacituzumab Govitecan in Pts With HR+/HER2- mBC"

685 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login